Se ha denunciado esta presentación.
Utilizamos tu perfil de LinkedIn y tus datos de actividad para personalizar los anuncios y mostrarte publicidad más relevante. Puedes cambiar tus preferencias de publicidad en cualquier momento.
DRL CASE STUDY  Prepared by –  Astha Bishnoi  Ashutosh Ranjan  Diksha Uniyal  Nikhil Sharma  Nirankar Royal  Swimmi Alaska
Basis of success of DRL prior tomid-90s   Reverse Engineering     Variant of new drug at low cost     Process innovatio...
Contd:   Weak intellectual property rights which facilitated    reverse engineering   Methyldopa – choice of product and...
   Started research programs by investing 4% of    revenue     Molecularrestructuring     Set up new drug development r...
Post mid 90s   Focus on two different segments     Capacity expansion     Building brands   Manufacture generics going...
Contd:   Acquisition of brands instead of company for    short-term growth   Tied-up with US firms for exporting drugs ...
Contd:   Drug discovery – focus on creating a lead    molecule (NCE) and selling it.   DRL acquired ARL because of which...
Contd:                                                                OTC and NDDS                                        ...
Post TRIPs Era   Should focus more on R&D for new chemical    entities (NCE)   U.S. FDI compliant to harness the growth ...
R & D expenditure of DRL                                number             40             35             30             25...
Patents granted in USPTA                                number          60          50          40          30            ...
ANDA Fillings                                  ANDA fillings          60          50          40          30              ...
THANK YOU
Próxima SlideShare
Cargando en…5
×

Dr reddy lab

7.919 visualizaciones

Publicado el

Publicado en: Educación, Empresariales
  • Inicia sesión para ver los comentarios

Dr reddy lab

  1. 1. DRL CASE STUDY Prepared by – Astha Bishnoi Ashutosh Ranjan Diksha Uniyal Nikhil Sharma Nirankar Royal Swimmi Alaska
  2. 2. Basis of success of DRL prior tomid-90s Reverse Engineering  Variant of new drug at low cost  Process innovation  Speed Looking at drug which have high growth and less sensitive to price fluctuation like anti-ulcerants Indian patent act, DCPO were favorable Two pronged approach towards export  Exported to countries where patents had expired  DRL adopted the route of exporting penultimate stage intermediates for bulk drugs
  3. 3. Contd: Weak intellectual property rights which facilitated reverse engineering Methyldopa – choice of product and timing of entry Foreign exchange regulation act Compare to US & Europe, production cost is less in India Produce bulk drugs where margin was good In 1990, dropping of anti-dumping charges which resulted in publicity Exploitation of HW act (ANDA)
  4. 4.  Started research programs by investing 4% of revenue  Molecularrestructuring  Set up new drug development research (NDDR)
  5. 5. Post mid 90s Focus on two different segments  Capacity expansion  Building brands Manufacture generics going off patent and innovator tie-ups Distribution system was reorganized Joint ventures in foreign markets  Countries with high population  Per capita consumption of medicines is high  Proximity to markets in near by countries e.g. Egypt, Brazil  Drug patent law not strongly in force
  6. 6. Contd: Acquisition of brands instead of company for short-term growth Tied-up with US firms for exporting drugs Fully owned subsidiary in US Marketing join ventures in Brazil Co-marketing and development agreement with Par Pharmaceuticals
  7. 7. Contd: Drug discovery – focus on creating a lead molecule (NCE) and selling it. DRL acquired ARL because of which it got five complementary brand, 3 manufacturing plants & 450 trained field staff. Licensed to multi-nationals for clinical trials and marketing Focused on areas of growing concern like diabetes and cancer
  8. 8. Contd: OTC and NDDS Value added and Branded Generics Conventional Dosage Forms Commodity Generics Intermediate and Bulk Drug Substances
  9. 9. Post TRIPs Era Should focus more on R&D for new chemical entities (NCE) U.S. FDI compliant to harness the growth opportunity in areas of contract manufacturing and research as US$45 billion of drugs would go off patent by 2007 in us alone Increase in U.S. ANDA fillings Exploring new markets Tie-up with foreign companies to in-license drugs Acquisition to become big firm – Roche’s API business, Betapharm
  10. 10. R & D expenditure of DRL number 40 35 30 25 20 nu 15 10 5 0 2005 2006 2007 2008 2009
  11. 11. Patents granted in USPTA number 60 50 40 30 number 20 10 0 UPTO 2005 2006 2007 2008 2009 2004
  12. 12. ANDA Fillings ANDA fillings 60 50 40 30 number 20 10 0 UPTO 2004 2005 2006 2007 2008 2009
  13. 13. THANK YOU

×